Compare Okta, Inc. (OKTA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Viatris Inc — how do they compare? Okta, Inc. trades at $136.01 (market cap $24.63B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Okta, Inc. is the larger of the two by market cap, and Viatris Inc pays a 2.73% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| OKTA | VTRS | |
|---|---|---|
Market Cap | $24.63B | $20.50B |
Sector | Technology | Health |
52-Week High | $154.62 | $17.59 |
52-Week Low | $62.93 | $8.74 |
Enterprise Value | $22.45B | $32.71B |
Dividend Yield | — | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
